Further studies revealed that duloxetine upregulated the protein expression of PPARγ in the prefrontal cortex and hippocampus, indicating its potential to suppress neuroinflammation associated with depression by inhibiting the transcription of proinflammatory genes through PPARγ [44, 45]. The gene discussed is PPARG; the disease is depressive symptom measurement.